K36 Therapeutics, Inc.
Clinical trials sponsored by K36 Therapeutics, Inc., explained in plain language.
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX-2001, alone or with another drug (darolutamide), in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to check safety, find the right dose, and …
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 24, 2026 05:18 UTC
-
New pill takes aim at Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase study tests an experimental pill called KTX-1001 in adults with multiple myeloma whose cancer has come back or stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow the disease. About 165 pa…
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC